Greenland Mines Reports $10.6 Million Net Loss and Significant Cash Influx in 2025

Greenland Mines Ltd, formerly known as Klotho Neurosciences, Inc., reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company did not generate any revenue during the year, maintaining a net loss of $10.6 million, an increase from a net loss of $6.2 million in 2024. This rise in losses was attributed to higher operating expenses, which totaled $7.1 million, compared to $5.5 million in the previous year. The increase in expenses was primarily driven by higher general and administrative costs, research and development expenses, and professional fees.

The company experienced a notable improvement in its working capital, which increased to approximately $7.2 million as of December 31, 2025, up from a negative working capital of $1.1 million in 2024. This improvement was largely due to a significant increase in cash and cash equivalents, which rose to $7.2 million from $63,741 in the prior year. The cash influx was primarily driven by financing activities, including proceeds from stock and warrant sales totaling approximately $13 million.

Strategically, Greenland Mines has expanded its operations through acquisitions, including the recent purchase of Greenland Mines Corp. in March 2026, which marks a shift towards the mining of critical and precious minerals. This acquisition is expected to enhance the company's growth trajectory and diversify its portfolio beyond pharmaceuticals. The company also holds a generic drug portfolio and a biosimilar biologics platform, alongside a proprietary gene therapy platform aimed at treating neurodegenerative diseases.

Operationally, Greenland Mines has a small workforce, with only two full-time employees as of March 30, 2026, supplemented by consultants. The company is focused on advancing its research pipeline, particularly in gene therapy for conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company plans to seek market approval for its gene therapy candidates in various regions, including the U.S., Canada, and Europe, and aims to establish partnerships to facilitate the development of its products.

Looking ahead, Greenland Mines faces challenges related to its ongoing financial losses and the need for additional funding to support its operations and development plans. The company has expressed substantial doubt about its ability to continue as a going concern without securing further capital. The management is actively exploring opportunities for additional financing and partnerships to ensure the successful execution of its business strategy and to navigate the competitive landscape of the biotechnology and pharmaceutical industries.